The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Concurrent durvalumab and radiation therapy followed by adjuvant durvalumab in patients with locally advanced urothelial cancer of bladder (DUART): Btcrc-GU15-023.
 
Monika Joshi
Consulting or Advisory Role - Sanofi
Research Funding - AstraZeneca (Inst); Pfizer (Inst)
 
Leonard Tuanquin
No Relationships to Disclose
 
Matthew Kaag
No Relationships to Disclose
 
Deepak Kilari
Honoraria - Exelixis
Consulting or Advisory Role - Exelixis; Sanofi
Speakers' Bureau - Exelixis; Genzyme; Genzyme (Inst); Janssen
Research Funding - Astellas Pharma (Inst)
Travel, Accommodations, Expenses - Bayer; Clovis Oncology; Exelixis; Janssen; Sanofi
 
Sheldon L. Holder
Employment - Hope Healthcare
Research Funding - Lilly
 
Hamid Emamekhoo
Consulting or Advisory Role - Bayer; Exelixis
Travel, Accommodations, Expenses - DAVA Pharmaceuticals
 
Alexander Sankin
No Relationships to Disclose
 
Suzanne B Merrill
No Relationships to Disclose
 
David DeGraff
No Relationships to Disclose
 
Joshua Warrick
No Relationships to Disclose
 
Hong Zheng
No Relationships to Disclose
 
Ralph J. Hauke
Stock and Other Ownership Interests - Aethlon
Honoraria - Best Doctors, Inc
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Merck (Inst); Novartis (Inst); Pharmacyclics (Inst); SOTIO (Inst); US Oncology (Inst)
Other Relationship - ABIM Subspecialty Board
 
Benjamin Adam Gartrell
No Relationships to Disclose
 
Mark N. Stein
Consulting or Advisory Role - Exelixis; Exelixis; Merck Sharp & Dohme
Research Funding - Advaxis (Inst); Bristol-Myers Squibb (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Janssen Oncology (Inst); Lilly (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Oncoceutics (Inst); Seagen (Inst); Suzhou Kintor Pharmaceuticals (Inst); Xencor (Inst)
 
Yousef Zakharia
Consulting or Advisory Role - Amgen; Bayer; Cardinal Health; Castle Biosciences; Eisai; Exelixis; Janssen; Novartis; Pfizer; Roche/Genentech; TTC Oncology
Travel, Accommodations, Expenses - Newlink Genetics
 
Joseph J. Drabick
Consulting or Advisory Role - Sanofi/Aventis